Full Text
PSS20 COST-UTILITY ANALYSIS OF A PRN (AS NEEDED) TREATMENT SCHEDULE WITH RANIBIZUMAB (LUCENTIS) IN WET AMD BASED ON CLINICAL EVIDENCE

Abstract

Authors

K Moeremans L Gerlier P Mitchell M Gallagher G Vincze

Back to Volume 13, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×